Burkitt lymphoma: click here to add to CAR-T?
In this issue of Blood, Samples et al report real-world outcomes from CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy in patients with relap
Related Articles
How I treat secondary acute myeloid leukemia
Treatment for patients with acute myeloid leukemia (AML) is being transformed for some patients, as targeted agents increase complete remission rates and s
Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome
Key PointsVarious types of leukemia share a hematopoietic stem and progenitor population (HSPC-like) associated with chemoresistance and poor outcome.HSPC-
Nilotinib attenuates vascular pathology in experimental cerebral malaria
Key PointsBCR-ABL drugs differentially modulate parasite and thrombin-induced activation of human brain endothelial cells.Nilotinib reduces vascular pathol
Low Iron Promotes Megakaryocytic Commitment of Megakaryocytic-Erythroid Progenitors in Human and Mice
Abstract. The mechanism underlying thrombocythemia in patients with iron deficiency anemia remains unknown. Iron metabolism is highly conserved in humans a
Thrombocytosis in Iron Deficiency Anemia
Abstract. Background: Thrombocytosis can be a result of a reactive process such as acute blood loss, infections, iron deficiency anemia (IDA) or a clonal d
IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy
Key PointsIL-10 secretion by DLBCL cells prevents the drift of the lymphoma microenvironment toward a highly immune-suppressive state.Hallmarks of IL-10 de
Enhanced α2-3–linked sialylation determines the extended half-life of CHO-rVWF
Key Pointsα2-3–linked sialylation is significantly increased on CHO-rVWF compared to human pdVWF.Enhanced α2-3–linked sialylation attenuates in vivo cleara
Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment
Distinct from other chimeric antigen receptor (CAR) therapies, B-cell maturation antigen–targeted CAR T-cell therapy can cause non-immune effector cell–ass
Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML
Key PointsVEN-DEC showed not inferior response to IA-12 in young/fit patients with untreated AML.VEN-DEC had fewer serious adverse events and shorter sever
Classic Hodgkin lymphoma in the cerebellum: a rare site for a common disease
A 53-year-old woman presented with a cerebellar tumor, 2 cm in diameter. Excisional biopsy showed a fibrotic lesion (panel A, hematoxylin and eosin staining, original…